Axcella Health Inc (AXLA) Actualités

Form 8-K - Current report

Form 8-K - Current report

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Axcella Announces Reverse Stock Split Effective September 19, 2023

– AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (Nasdaq: AXLA), a...

Form 8-K - Current report

Form 8-K - Current report

Axcella Granted Patent for Long COVID Fatigue Treatment

Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate...